Bruker stock is coming off a strong year, with the share price up 43.3% over the past 12 months, while both market multiples and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach currently point to the shares trading below that intrinsic value.

• Over the past year, Bruker has returned 43.3%, which puts more focus on whether the current price still leaves a margin between market value and intrinsic value.
• For a science and instrumentation business like Bruker, expectations around steady demand for its equipment and services can support the intrinsic value. However, any pressure on research budgets or capital spending at its customers may weigh on how much of that value is eventually realized.
• Bruker screens as undervalued on most checks, with the broader set of valuation tests suggesting the stock looks cheap on 5 out of 6 metrics, as seen in the valuation summary.

The issue now is whether Bruker’s current share price still offers enough upside relative to this intrinsic value estimate to appeal to investors focused on valuation.

Does Bruker Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here is built on cash flow projections rather than earnings multiples. For Bruker, the latest twelve month free cash flow is about $31.3 million, and analysts and model estimates together point to cash flows that are then discounted back to today to account for risk and the time value of money.

On this basis, the DCF model points to an estimated intrinsic value of about $83 per share. Compared with the current share price, this implies the stock is trading at roughly a 28.2% discount to that intrinsic value. The gap suggests the market price is not fully reflecting the cash flows currently projected for Bruker.

Overall, the Discounted Cash Flow workup indicates Bruker stock currently appears undervalued relative to its estimated intrinsic value.

Our Discounted Cash Flow (DCF) analysis suggests Bruker is undervalued by 28.2%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Is Bruker Still Cheap on Sales?

For Bruker, the P/S ratio is a useful cross-check because revenue can be more stable than earnings for equipment and instrumentation companies.

Bruker currently trades on a P/S of about 2.6x, which sits below both the Life Sciences industry average of 3.9x and a peer group average of 8.0x. In addition, a tailored fair P/S ratio of about 4.1x, which reflects the company’s profile within its industry, stands above the current multiple. That gap indicates the stock is pricing in less value per dollar of sales than the framework suggests might be reasonable.

Taken together, Bruker stock appears attractively valued on its P/S multiple relative to both sector benchmarks and the modelled fair ratio.

The Bruker Narrative: What Would Justify Today's Price?

For Bruker, Simply Wall St Narratives sit between the valuation work above and the expectations that would need to play out for the stock to be worth materially more or less than today’s price. They are found on the company’s Community page. Instead of giving a single figure from a ratio or model, they describe the type of future in growth, margins and earnings that number relies on, so you can see whether reality tracks it.

One of the top community narratives on Bruker: 7% overvalued

"Growing adoption and placements in consumables/software-driven businesses are enhancing recurring revenue streams and earnings stability, which should steadily lift overall net margins as these segments represent a greater share of total sales..."

Do you think there's more to the story for Bruker? Head over to our Community to see what others are saying!

The Bottom Line

For Bruker, both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point in the same direction, with the stock screening as undervalued rather than stretched. The key question from here is whether the business can sustain the cash flows and sales profile that underpin that intrinsic value and the fair P/S ratio. If demand from research and clinical customers holds up and margins do not come under unexpected pressure, the current discount could prove attractive. However, if spending softens, the gap between price and estimated value may be justified rather than an opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.